|
市場調査レポート
商品コード
1219652
難聴疾患治療の世界市場規模、シェア、産業動向分析レポート:疾患タイプ別、製品タイプ別、エンドユーザー別、地域別展望と予測、2022年~2028年Global Hearing Loss Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type, By Product, By End-user, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
難聴疾患治療の世界市場規模、シェア、産業動向分析レポート:疾患タイプ別、製品タイプ別、エンドユーザー別、地域別展望と予測、2022年~2028年 |
出版日: 2023年01月31日
発行: KBV Research
ページ情報: 英文 192 Pages
納期: 即納可能
|
難聴疾患治療の世界市場規模は、予測期間中にCAGR4.6%で成長し、2028年には160億米ドルに達すると予測されます。
難聴疾患は、感音性難聴、伝音性難聴、混合性難聴の3つに分類することができます。感音性難聴は、内耳の問題で起こる難聴で、神経性難聴とも呼ばれます。伝音難聴は、切頭骨、槌骨、アブミ骨(鼓膜、外耳道、中耳とその小骨)に問題があるために起こります。
混合性難聴は、中耳または外耳の伝導性障害と蝸牛(内耳)または聴神経の感音性障害の組み合わせから生じます。難聴の種類としては、聴覚リハビリテーション、聴覚神経障害、騒音性難聴、平衡感覚障害、突発性難聴、耳硬化症、耳鳴り、メニエール病などが挙げられます。
COVID-19インパクト分析
心臓弁、整形外科用インプラント、聴覚診断装置、眼内レンズなどのデバイスの需要は下降曲線を描いています。また、難聴治療市場も縮小傾向にあります。市場を管理する重要なプレーヤーは、難聴疾患治療市場の販売の減少を説明しています。さらに、人工内耳埋め込みプロセスの遅れは、売上げの減少を観察しています。COVID-19のパンデミックは、聴覚士の中でテレヘルスの実装を増加させました。
市場成長要因
難聴患者数の増加
2019年、世界人口の約5%にあたる4億6600万人が難聴障害を持ち、その内訳は大人4億3200万人&子供3400万人で、その結果、生活の質に影響を及ぼしていると言われています。これらの人々の多くは、中低所得国に住んでいます。難聴に直面した場合、7,500億米ドルのコストがかかると言われています。一般的に、難聴のほとんどは公衆衛生対策によって回避することができると推奨されています。このように、世界中で難聴の症例数が増加していることから、難聴治療に対する需要が高まり、予測期間中に難聴市場が成長することが予想されます。
高齢者人口の増加
世界保健機関(WHO)によると、人口に占める60歳以上の割合と量が拡大しています。2019年、60歳以上の高齢者の量は10億人であることが確認されました。この量は、2030年には14億人、2050年には21億人にまで増加すると予測されています。この成長は、特に発展途上国において、今後数年でエスカレートしていくでしょう。高齢化が進めば、長期介護やプライマリーヘルスケアの需要が高まり、より優れた、より多くの訓練を受けた従業員が必要になります。高齢者は、主に老年症候群として知られる様々な複雑な健康状態の出現によって区別することができます。このことは、難聴治療市場の成長の増加につながるでしょう。
市場抑制要因
訓練を受けた専門家の不足
聴覚検査機器は、技術的に高度に発達しています。これらの機器を埋め込むためには、多くの正確さと精度が必要とされます。また、聴力検査機器の使用方法は非常に高度な学習が必要です。患者の耳にこれらの機器を取り付ける外科医は、訓練を受け、専門的に熟練している必要があります。しかし、これらの装置を正しく設置するために必要な、適切なスキルが不足しているのです。さらに、最新の補聴器の顕著な量は、世界中のいくつかの市場のプレーヤーによって開始されています。これらの要素は、難聴治療市場の発展を決定的に制限しています。
製品の展望
難聴治療市場は、製品によって機器と医薬品に分けられます。医薬品分野は、新しい医薬品のイントロダクションより成長すると予測されています。聴覚障害には、さまざまな種類の薬剤があります。これは、予期せぬ難聴に対するステロイドや、耳の感染症に対する炎症・抗生物質製品など、質の高い治療薬で構成されています。しかし、薬で改善しない患者には、医師がALD(Assistive Listening Devices)や補聴器を勧める。したがって、専用の新しい治療法に対する需要が、業界の収益性の高い発展を可能にしているのです。
疾患タイプ別展望
難聴疾患治療市場は、疾患タイプに基づいて、伝導性難聴、感音性難聴、混合型(伝導性&感音性)に細分化されます。2021年の難聴疾患治療市場では、感音性難聴分野が最も高い収益シェアを示しています。これは、感音性難聴が患者の間で最も一般的な症状であることと、治療法の選択肢が増加していることによります。さらに、腫瘍、自己免疫性内耳疾患、ウイルス、疾患感染などの発生が感音性難聴の主要なリスク要素となっています。
エンドユーザーの展望
エンドユーザー別では、難聴疾患治療市場は、病院、耳鼻科クリニック、外来クリニックに二分されます。2021年の難聴疾患治療市場は、耳鼻科クリニック分野が最大の売上高シェアを占めています。耳科クリニックは、耳に関連する疾患の治療&診断に特化したクリニックです。多くの民間医師が耳の病気の治療の専門家であり、民間の耳鼻咽喉科の健康センターを立ち上げているため、このセグメントでは難聴治療装置の需要が拡大しています。また、一般的にこれらの医療センターは、患者が定期検診に頻繁に訪れる地元の住宅地で見つけやすくなっています。
地域別の展望
地域別に見ると、難聴疾患治療市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2021年、アジア太平洋地域は難聴疾患治療市場において顕著な成長率を調達しました。アジア太平洋地域の市場成長は、主に耳の病気の高い有病率と高齢者人口の増加によって駆動されています。新興国市場は、難聴治療市場に魅力的で大きな成長のチャンスを与えています。また、これらの国々における病院や耳鼻咽喉科クリニックの発展が、難聴治療市場の需要を拡大しています。
List of Figures
The Global Hearing Loss Disease Treatment Market size is expected to reach $16 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period.
Hearing loss is a serious circumstance that has a complicated effect on the individual's development & growth. It could lead to loneliness & isolation and can also considerably decreases the quality of life. Hearing loss may have a great influence on the daily life of the individual. From a young age, the person might encounter speech & language skills problems at school and a social environment.
The hearing loss problem is increasing gradually due to many causes. Aside from hereditary reasons, age is one of the critical factors for hearing loss. The commonly known hearing loss type is age-related hearing loss (or presbycusis). Loud noise is another primary cause that affects delicate inner-ear cells. Exposure to loud noise because of the utilization of hearing devices such as occupational noises, earbuds, and recreational noises contributes remarkably to hearing loss in young people.
The hearing loss diseases can be classified into three classes sensorineural hearing loss, conductive hearing loss, and mixed hearing loss. Sensorineural hearing loss occurs because of inner ear problems, also seen as nerve-related hearing loss. Conductive hearing loss happens because of problems with the incus, malleus, & stapes (eardrum, ear canal, or middle ear & its little bones).
The mixed hearing loss originates from a combination of conductive injury in the middle or outer ear & sensorineural injury in the cochlea (inner ear) or auditory nerve. According to the disease type, common hearing loss diseases are aural rehabilitation, auditory neuropathy, noise-induced hearing loss, balance disorders, sudden deafness, otosclerosis, tinnitus & meniere's disease.
COVID-19 Impact Analysis
The demand for devices like heart valves, orthopedic implants, audiology diagnostics devices, & intraocular lenses displays a downward curve. In addition, the hearing loss disease treatment market has also witnessed a downfall. Crucial players managing the market have described a decrease in the selling of the hearing loss disease treatment market. Furthermore, the cochlear implantation process delay has observed a decline in sales. The COVID-19 pandemic has increased the implementation of telehealth in the midst of audiologists.
Market Growth Factors
Increase in number of hearing loss patients
In 2019, 466 million people, or around 5% of the world's population, had the hearing loss disability, accounting for 432 million adults & 34 million children, thus, influencing their quality of life. Most of these people live in middle- & low-income nations. Hearing loss that is not confronted poses a total cost of USD 750 billion. Generally, it is recommended that most hearing loss diseases can be averted through public health measures. Thus, due to the rising number of cases of hearing loss across the globe, the demand for the hearing loss disease treatment has increased which will result in the growth of this market during the projected period.
Growing population of elderly people
According to World Health Organization, the proportion and amount of people who are aged 60 years and above in the population are expanding. It was observed that in 2019, the amount of people aged 60 years and above was 1 billion. This amount is predicted to rise to 1.4 billion by 2030 and 2.1 billion by 2050. This growth will escalate in the upcoming years, especially in developing nations. Aging would boost the demand for long-term care & primary health care, thus, needing a better & larger trained employee. Elderly people can be distinguished by the appearance of various complex health conditions, mainly known as geriatric syndromes. This will lead to an increase in the growth of the hearing loss disease treatment market.
Market Restraining Factors
Shortage of trained professionals
Audiology devices are technologically highly developed. A lot of accuracy & precision are needed for the implantation of these devices. Additionally, the learning curve for utilizing audiology devices is exceptionally high. The surgeon must be trained & professionally skilled who are installing these devices on the ear of the patient. But there is a shortage of required & appropriate skills for the correct installation of these devices. Furthermore, a remarkable amount of the latest hearing aids is being launched by several market players all over the world. These components is crucially restricting the development of the hearing loss disease treatment market.
Product Outlook
Based on the product, the hearing loss disease treatment market is divided into devices and drugs. The drugs segment is predicted to grow because of the introduction of new medicinal products. Various kinds of drugs are available for hearing problems. This consist quality treatments, like steroids for unexpected hearing loss or inflammation & antibiotic products for ear infections. Nevertheless, doctors recommend ALDs (Assistive Listening Devices) or hearing aids for those patients that don't exhibit improvement with medicines. Therefore, the demand for dedicated and novel treatment choices has made profitable development possible for the industry.
Disease Type Outlook
On the basis of disease type, the hearing loss disease treatment market is fragmented into conductive hearing loss, sensorineural hearing loss, and mixed (conductive & sensorineural). In 2021, the sensorineural hearing loss segment witnessed the highest revenue share in the hearing loss disease treatment market. This is because sensorineural hearing loss is the most ordinary condition noticed among patients and the growing amount of treatment choices. Furthermore, rising occurrence of tumours, autoimmune inner ear disease & viruses, or disease infection are among the leading risk elements for sensorineural hearing loss.
End - User Outlook
By end-user, the hearing loss disease treatment market is bifurcated into hospitals, otology clinics, and ambulatory clinics. In 2021, the otology clinics segment dominated the hearing loss disease treatment market with the largest revenue share. The otology clinics are specific for treating & diagnosing diseases associated with the ear. The demand for hearing loss treatment devices is growing in this segment as many private doctors are specialists in treating ear diseases and are starting private ENT health centers. Additionally, these health centers generally are easier to find in the local residential regions where patients frequently visit for fixed check-ups.
Regional Outlook
Region-wise, the hearing loss disease treatment market is analysed across North America, Europe, Asia Pacific and LAMEA. In 2021, the Asia Pacific region procured a remarkable growth rate in the hearing loss disease treatment market. Market growth in the Asia Pacific region is driven mainly by the high prevalence of ear diseases and the growing elderly population. Developing markets provide attractive and significant growth chances for the hearing loss disease treatment market. In addition, the development of hospitals & ENT clinics in these nations has expanded the demand for the hearing loss disease treatment market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Astellas Pharma, Inc, WS Audiology A/S, Otonomy, Inc, Sensorion, Frequency Therapeutics, Inc, Acousia Therapeutics GmbH, Pipeline Therapeutics, Inc, Audina Hearing Instruments, Inc, and Audifon GmbH & CO. KG.
Strategies Deployed in Hearing Loss Disease Treatment Market
Dec-2022: Frequency Therapeutics, Inc., announced that it has dosed the first patient in the Phase 1b study of FX-345. FX-345 is a combination of two small molecules, which is designed to restore inner ear cells needed for hearing.
Jul-2022: Astellas Pharma, Inc. came into collaboration with Mogrify Limited, a biopharmaceutical company. Under this collaboration, Astellas Pharma, Inc. would be using Mogrify's proprietary direct cellular reprogramming platform to determine unknown varieties of transcription factors involved in cell differentiation to develop new cochlear hair cells.
Sep-2022: WS Audiology partnered with Sony Corporation, renowned Japanese consumer electronics provider. Under this partnership, both organizations would offer self-fitting OTC hearing aids. Moreover, WSA would provide its hearing aid technology, adding its distribution abilities in the professional channel.
Sep-2021: Sensorion came into collaboration with Sonova, a global leader in innovative hearing care solutions. Through this collaboration, Sensorion would be able to plan to present genetic analysis to the routine diagnosis of progressive hearing loss in adults. Moreover, Sensorion with Sonova would be pushing future standards of hearing loss therapy and diagnosis.
Aug-2020: Otonomy, Inc. signed an agreement with KYORIN Pharmaceutical Co., Ltd, the manufacturers and sellers of prescription medicines and quasi-drugs. Under this agreement, Otonomy, Inc would be provided with sole worldwide rights to create, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.
Oct-2019: Otonomy, Inc. collaborated with Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of Adeno-associated virus (AAV)-based gene therapies. Under this collaboration, both organizations would be working to co-develop and co-commercialize an AAV-based gene therapy to fix hearing in patients with sensorineural hearing loss. Furthermore, this collaboration would allow Otonomy, Inc. to elaborate the creative pipeline across the market possibilities in neurotology with genetic and acquired conditions of hearing loss.
Jul-2019: Frequency Therapeutics, Inc., signed an agreement with Astellas Pharma, Inc., a Japanese multinational pharmaceutical company. Under this agreement, both organizations would grow and commercialize Frequency's regenerative therapeutic candidate, FX-322. Moreover, Frequency Therapeutics, Inc., is keen to advance FX-322 for patients with sensorineural hearing loss and further display the potential of the platform for progenitor cell activation.
Market Segments covered in the Report:
By Disease Type
By Product
By End-user
By Geography
Companies Profiled
Unique Offerings from KBV Research